Abstract:Polycystic ovary syndrome (PCOS) is a common metabolic disorders among women of reproductive age worldwide. It is also one of the common causes of female infertility. The effect of probiotics has been gradually revealed and recognized by the public. Previous studies have shown that probiotic intervention can effectively improve intestinal microbiome and relieve metabolic diseases represented by obesity and type 2 diabetes. Although a few studies have investigated the intestinal microbiota profiles of women with PCOS, the regulatory effect of the probiotic Bifidobacterium lactis V9 has yet to be revealed. We hope that Bifidobacterium lactis V9 can improve the metabolism of patients by regulating the intestinal flora, thus slowing down the disease. To address this gap, in this study, metagenomics and metabolomics were used together to analyze the effects of Bifidobacterium lactis V9 on patients with PCOS. Nine patients with PCOS were selected to comsume 15 billion probiotic Bifidobacterium lactis V9 every day during the intervention period. Fecal samples were collected from patients at week 0, week 1, week 2 and week 4. The results showed that Bifidobacterium lactis V9 had stable colonization ability in the intestinal tract of patients. The abundance of Bifidobacterium and Faecalibacterium significantly increased, while that of other bacteria significantly decreased, including Clostridium, Collinsella, Ochrobactrum, Streptococcus, Prevotella, Coprococcus and Actinomyces and the opportunistic pathogen Klebsiella is almost gone. The results of metabonomic analysis showed that the metabolic level of glucocorticoids was significantly reduced and the metabolic level of short chain fatty acids such as acetic acid, propionic acid and butyric acid was significantly increased. PPAR signal pathway and adipocytokine signal pathway associated with insulin resistance and lipid metabolism were decreased significantly based on PICRUSt. Furthermore, the regulation functions of Bifidobacterium lactis V9 on intestinal microbiome in patients with polycystic ovary syndrome was further revealed based on the analysis of the network interaction between different genus and metabolic functional units. As expected, Bifidobacterium lactis V9 can improve the body's metabolism by regulating the intestinal flora of patients with PCOS, which is conducive to slowing down the clinical symptoms of patients. To sum up, this study revealed the changes of intestinal microbiome and metabolites of patients with PCOS after 4 weeks of consumption of probiotic Bifidobacterium lactis V9 by using multi-group technique including metagenomics and metabolomics. Although we have observed that Bifidobacterium lactis V9 is beneficial to patients with PCOS, the regulatory mechanism needs to be revealed in larger clinical trials. At the same time, we need to find biomarkers and target them for the treatment of metabolic diseases through probiotics. The results of this study provide new insights into the treatment of PCOS and offer objective and detailed data supporting the use of probiotic treatments for metabolic diseases.

Modified Banxia Xiexin Decoction Ameliorates Polycystic Ovarian Syndrome With Insulin Resistance by Regulating Intestinal Microbiota

Modified Cangfu Daotan decoction ameliorates polycystic ovary syndrome with insulin resistance via NF-κB/LCN-2 signaling pathway in inflammatory microenvironment

Inulin and metformin ameliorate polycystic ovary syndrome via anti-inflammation and modulating gut microbiota in mice.

Gut microbiota–bile acid–interleukin-22 axis orchestrates polycystic ovary syndrome

Guizhi Fuling Wan, Chinese Herbal Medicine, Ameliorates Insulin Sensitivity in PCOS Model Rats With Insulin Resistance via Remodeling Intestinal Homeostasis

Effects of Invigorating Spleen and Removing Phlegm Decoction on Insulin Resistance and Serum Adipokine Levels in PCOS Rats

Zishen Qingre Lishi Huayu Recipe May Ameliorate the Symptoms of PCOS Model Rats via Alleviating Systemic and Ovarian Inflammation

Shaoyao-Gancao Decoction Ameliorates the Inflammation State in Polycystic Ovary Syndrome Rats via Remodeling Gut Microbiota and Suppressing the TLR4/NF-κB Pathway

Effects of inulin on intestinal flora and metabolism-related indicators in obese polycystic ovary syndrome patients

Berberine Improves the Symptoms of DHEA-Induced PCOS Rats by Regulating Gut Microbiotas and Metabolites

Effects of Bu Shen Hua Zhuo formula on the LPS/TLR4 pathway and gut microbiota in rats with letrozole-induced polycystic ovary syndrome

Exploring the efficacy and mechanism of Bailing capsule to improve polycystic ovary syndrome in mice based on intestinal-derived LPS-TLR4 pathway

Association between Polycystic Ovary Syndrome and Gut Microbiota

Intestinal Flora is a Key Factor in Insulin Resistance and Contributes to the Development of Polycystic Ovary Syndrome

Diversity of the Gut Microbiota in Dihydrotestosterone-Induced PCOS Rats and the Pharmacologic Effects of Diane-35, Probiotics, and Berberine.

Dietary -Linolenic Acid-Rich Flaxseed Oil Exerts Beneficial Effects on Polycystic Ovary Syndrome Through Sex Steroid Hormones-Microbiota-Inflammation Axis in Rats

Probiotic Bifidobacterium Lactis V9 Regulates the Intestinal Microbiome in Patients with Polycystic Ovary Syndrome

Gut Microbiota As a Potential Target for Treatment of Polycystic Ovary Syndrome

β-Sitosterol Ameliorates Endometrium Receptivity in PCOS-Like Mice: The Mediation of Gut Microbiota

Structural and functional profiles of the gut microbial community in polycystic ovary syndrome with insulin resistance (IR-PCOS): a pilot study